A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2).

Trial Profile

A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 29 Sep 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 28 Feb 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top